(Press-News.org) MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 8, 2025, AT 6 P.M. EST) – A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia. The study was co-led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Many veterans and doctors have long questioned whether Agent Orange exposure during the Vietnam War contributed to cases of MDS, a type of blood cancer. The contaminated chemical is linked to several cancers, but a link to MDS was unclear. This created real barriers for exposed veterans with MDS who are seeking care and disability benefits.
“This study has been a personal quest,” said Mikkael Sekeres, M.D., chief of hematology at Sylvester. “I see veterans who develop these conditions and need expensive medical care, but I can’t write a letter that establishes causality because, before this study, we hadn’t clearly linked Agent Orange to MDS.”
Sekeres will present the full analysis in a poster presentation Dec. 8, at the 2025 American Society of Hematology (ASH) annual meeting in Orlando.
MDS is a bone marrow cancer that develops slowly over a lifetime of accumulated genetic mutations. MDS affects up to 20,000 Americans each year, typically over 70. Some aggressive cases of MDS eventually progress to acute myeloid leukemia.
“MDS isn’t a one-hit wonder,” Sekeres said. “Patients have one genetic mutation that occurs, then another, then another. It takes decades for those mutations to develop, and with an exposure like Agent Orange, patients can acquire that first mutation at a younger age than they normally would.”
About 2.6 million U.S. service members may have been exposed to Agent Orange during the Vietnam War. The U.S. government used this chemical as a defoliant, but it accidentally contained one of the most dangerous industrial chemicals ever produced, a toxic form of dioxin. Research already links Agent Orange exposure to blood cancers, including types of lymphoma, multiple myeloma and leukemia.
Studies had not clearly shown a link between Agent Orange exposure and MDS mainly because data were unavailable. “No one studied this before because there haven’t been organized registries with the data needed to make this connection," Sekeres said. Only one older study attempted to explore a possible connection, but it lacked diagnostic confirmation and had incomplete exposure data.
That data gap has caused veterans to go unrecognized for their disease. This new analysis represents the first nationwide, prospective effort able to connect confirmed MDS diagnoses with documented Agent Orange exposure.
The data used in the study come from the MDS Natural History Study, which includes genetic information from bone marrow and data on environmental exposures. The research team examined data from 2,115 people, 130 of whom self-reported Agent Orange exposure.
The study found that, compared to those who had no exposure, people exposed to Agent Orange were diagnosed with MDS at younger ages. They also had a higher burden of harmful mutations and were more likely to exhibit high-risk genetic patterns seen in toxin-related MDS cases.
Clinically, people exposed to Agent Orange were nearly twice as likely to see their disease progress within the first two years after diagnosis. Thankfully, overall survival between the two groups was similar. “The progression finding was surprising,” said Sekeres. “We didn’t expect that signal to be as strong as it was.”
Across every analysis, the results aligned: exposed patients were younger at diagnosis, had more mutations, faced higher-risk disease and were more likely to progress early. “It’s a consistent signal across the different areas where we look — age of onset, genetics, progression,” Sekeres said.
Veterans who self-reported Agent Orange exposure were significantly more likely to be Black, at rates higher than those seen in Vietnam service demographics. “This toxin may have hit a particularly vulnerable population,” Sekeres said. Importantly, he noted, the data showed no connection between these patterns and smoking — a potential confounding factor.
For veterans, these results may aid future efforts to improve recognition, screening and access to care. Without official acknowledgment of this link, patients with MDS have struggled to qualify for service-connected benefits. The findings should also prompt clinicians to ask about environmental and military exposures, especially when MDS occurs at a younger age.
The team is preparing follow-up analyses using national veteran databases to strengthen and refine the results. For Sekeres, the goal is simple: ensure that veterans with MDS receive the care they need.
“Veterans have been waiting a long time for someone to take this seriously,” he said. “If our work can move the needle even a little, that feels incredibly meaningful.”
about Sylvester research on the InventUM blog and follow @SylvesterCancer on X for the latest news on its research and care.
# # #
Poster Title: Exposure to agent orange and risk of myelodysplastic syndromes
Date, Time and Location: Dec. 8, 6-8PM; OCCC – West Halls B3-B4
END
Two clinical studies demonstrate high response rates by patients with two hard-to-treat and aggressive blood cancers
Pivekimab sunirine (PVEK) targets the CD123 antigen, which is overexpressed in both diseases
Frontline triplet regimen including PVEK shows promise for hard-to-treat AML in patients who are not eligible for intensive chemotherapy
PVEK monotherapy demonstrates strong responses, enables stem cell transplant for high-risk subgroup of BPDCN patients
ORLANDO, DECEMBER 8, 2025 – Researchers from The ...
Alexandria, VA, USA – Members of the International Association for Dental, Oral, and Craniofacial Research (IADR) have elected George Belibasakis, Karolinska Institutet, Stockholm, Sweden to serve as Vice-president. His term will commence at the conclusion of the 104th General Session of the IADR, which will be held in conjunction with the 55th Annual Meeting of the AADOCR and the 50th Annual Meeting of the Canadian Association for Dental Research, from March 25-28, 2026 in San Diego, CA, USA.
Belibasakis is currently Professor of Clinical Oral Infection Biology, Head of the Division of Oral Health and Periodontology, and Head of Research at the Department of Dental Medicine, ...
Quantum technologies from ultrasensitive sensors to next-generation information processors depend on the ability of quantum bits, or qubits, to maintain their delicate quantum states for a sufficiently long time to be useful.
One of the most important measures of this stability is the spin coherence time. Unfortunately, qubits may lose coherence because their environment is “noisy,” for example, due to the presence of nuclear isotopes or other interference that disturbs the qubit.
Two-dimensional (2D) materials—or atomically thin sheets—can offer quiet environments for qubits, as their reduced thickness naturally lowers the number of isotopes that interact ...
University of Phoenix College of Doctoral Studies announces a new white paper, “Leadership Opportunities for Increasing Employee Value through Artificial Intelligence,” authored by Andrew C. Lawlor, PhD, and Pamayla E. Darbyshire, DHA, MSN/CNS, both Fellows at the Center for Educational and Instructional Technology Research (CEITR). The paper examines how leaders can use AI, especially generative AI, to address skills gaps, restore worker autonomy, and shift employees from repetitive tasks to higher-value activities.
The authors draw upon the University’s Career Optimism Index® study and other current research, ...
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 8, 2025, AT 4:30 P.M. EST) – A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.
In just a few years, treatment options for aggressive lymphoma have rapidly advanced. However, many patients show a consistent pattern: powerful new therapies act quickly but often fail to keep the lymphoma at bay permanently, says Jay Spiegel, M.D., a transplant and cellular therapy physician at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Spiegel ...
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukaemia (T-ALL).
The world-first gene therapy (BE-CAR7) uses base-edited immune cells to treat previously untreatable T-cell leukaemia and help patients achieve remission, offering new hope for families facing this aggressive cancer. Base-editing is an advanced version of CRISPR technology, that can precisely change single ...
An international team led by the University of Michigan has introduced new methods that reveal which regions of the brain were active throughout the day with single-cell resolution.
Using mouse models, the researchers developed an experimental protocol and a computational analysis to follow which neurons and networks within the brain were active at different times. Published in the journal PLOS Biology, the study provides new insights into brain signaling during sleep and wakefulness, which hints at the bigger questions and goals that motivated the work.
"We undertook this difficult study to understand fatigue," ...
Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of age-related macular degeneration (AMD).
A new study, published today in Nature Communications, reveals the specific genetic factors linked to the presence of reticular pseudodrusen - deposits which drive vision loss and are found on the retina of up to 60 per cent of people with advanced AMD.
The research, led by the Centre for Eye Research Australia, WEHI and the University of Melbourne, offers a promising new target for treatments aimed at the most severe ...
Embargoed for release until 5:00 p.m. ET on Monday 8 December 2025
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization ...
About The Study: Among patients with sepsis, precision immunotherapy targeting macrophage activation–like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo.
Corresponding Author: To contact the corresponding author, Evangelos J. Giamarellos-Bourboulis, MD, PhD, email egiamarel@med.uoa.gr.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.24175)
Editor’s Note: Please see the article for additional information, including other ...
